Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD

OBJECTIVE: To compare the diagnostic performance of PET with the amyloid ligand Pittsburgh compound B (PiB-PET) to fluorodeoxyglucose (FDG-PET) in discriminating between Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD). METHODS: Patients meeting clinical criteria for AD (n = 62) a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rabinovici, G.D., Rosen, H.J., Alkalay, A., Kornak, J., Furst, A.J., Agarwal, N., Mormino, E.C., O'Neil, J.P., Janabi, M., Karydas, A., Growdon, M.E., Jang, J.Y., Huang, E.J., DeArmond, S.J., Trojanowski, J.Q., Grinberg, L.T., Gorno-Tempini, M.L., Seeley, W.W., Miller, B.L., Jagust, W.J.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2011
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3236517/
https://ncbi.nlm.nih.gov/pubmed/22131541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e31823b9c5e
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars